Mpox (formerly monkeypox): pathogenesis, prevention, and treatment

Lu, Junjie1; Xing, Hui1; Wang, Chunhua1; Tang, Mengjun1; Wu, Changcheng2; Ye, Fan1; Yin, Lijuan3; Yang, Yang4; Tan, Wenjie2; Shen, Liang1

2023-12-27

10.1038/s41392-023-01675-2

SIGNAL TRANSDUCTION AND TARGETED THERAPY   影响因子和分区

2095-9907

2059-3635

In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries across Europe and America and rapidly spread to more than 100 countries and regions. The World Health Organization declared the outbreak to be a public health emergency of international concern due to the rapid spread of the Mpox virus. Consequently, nations intensified their efforts to explore treatment strategies aimed at combating the infection and its dissemination. Nevertheless, the available therapeutic options for Mpox virus infection remain limited. So far, only a few numbers of antiviral compounds have been approved by regulatory authorities. Given the high mutability of the Mpox virus, certain mutant strains have shown resistance to existing pharmaceutical interventions. This highlights the urgent need to develop novel antiviral drugs that can combat both drug resistance and the potential threat of bioterrorism. Currently, there is a lack of comprehensive literature on the pathophysiology and treatment of Mpox. To address this issue, we conducted a review covering the physiological and pathological processes of Mpox infection, summarizing the latest progress of anti-Mpox drugs. Our analysis encompasses approved drugs currently employed in clinical settings, as well as newly identified small-molecule compounds and antibody drugs displaying potential antiviral efficacy against Mpox. Furthermore, we have gained valuable insights from the process of Mpox drug development, including strategies for repurposing drugs, the discovery of drug targets driven by artificial intelligence, and preclinical drug development. The purpose of this review is to provide readers with a comprehensive overview of the current knowledge on Mpox.

SCI

英语

通讯

National Natural Science Foundation of China (National Science Foundation of China)[82002192] ; National Natural Science Foundation of China["2022CFB539","2022CFD107"] ; Natural Science Foundation of Hubei Province[Q20222605] ; Young and middle-aged Talents Project of Hubei Provincial Education Department[2021KPGJ06] ; Scientific Research Ability Cultivation Fund of Hubei University of Arts and Science["2022YL05B","2022YL12A"]

Biochemistry & Molecular Biology ; Cell Biology

Biochemistry & Molecular Biology ; Cell Biology

WOS:001130383200001

SPRINGERNATURE

Web of Science

1.Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Affiliated Hosp, Xiangyang 441021, Hubei, Peoples R China
2.Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, NHC Key Lab Biosafety, Beijing 102206, Peoples R China
3.Tianjin Univ Sci & Technol, Coll Biotechnol, Tianjin 300457, Peoples R China
4.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis, Shenzhen Key Lab Pathogen & Immun,Hosp 2,State Key, Shenzhen 518112, Peoples R China

Lu, Junjie,Xing, Hui,Wang, Chunhua,et al. Mpox (formerly monkeypox): pathogenesis, prevention, and treatment[J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY,2023,8(1).

Lu, Junjie.,Xing, Hui.,Wang, Chunhua.,Tang, Mengjun.,Wu, Changcheng.,...&Shen, Liang.(2023).Mpox (formerly monkeypox): pathogenesis, prevention, and treatment.SIGNAL TRANSDUCTION AND TARGETED THERAPY,8(1).

Lu, Junjie,et al."Mpox (formerly monkeypox): pathogenesis, prevention, and treatment".SIGNAL TRANSDUCTION AND TARGETED THERAPY 8.1(2023).